March 25, 2024
The Third Circuit refused Monday to reconsider a ruling that found AbbVie was unable to show a lower court went against precedent or made errors when ordering the drugmaker to turn over attorney communications from a patent case allegedly meant to delay an AndroGel rival.
March 11, 2024
The Third Circuit has found that AbbVie was unable to show that a Pennsylvania federal court went against precedent or made an error when ordering the drugmaker to turn over attorney communications from a "sham" patent case allegedly meant to delay AndroGel competitors.
February 22, 2024
The Third Circuit has denied AbbVie Inc.'s bid to block a Pennsylvania federal court's order to turn over attorney communications from a patent case allegedly cooked up just to extend the company's monopoly on a testosterone drug, but the appellate court's explanation remained under seal Thursday.
November 29, 2023
Judges on a Third Circuit panel were skeptical Wednesday of arguments from AbbVie Inc. that a lower court's ruling on discovery of attorney communications in a "sham" patent case would open the floodgates to privilege challenges any time a drug company files a suit that slows down a competitor.